Research programme: atherosclerosis therapies - Merck & CoAlternative Names: Atherosclerosis therapies research programme - Merck & Co
Latest Information Update: 31 Mar 2010
At a glance
- Originator Merck & Co
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Atherosclerosis
Most Recent Events
- 05 Mar 2008 This programme is still in active development
- 17 May 2005 Preclinical trials in Atherosclerosis in USA (unspecified route)